Liu J, Tan L, Zhang H, Li H, Liu X, Yan Z, Chen J, Yang H, Zhang D
Department of Otolaryngology, the First Affiliated Hospital of Harbin Medical University, Harbin, China.
Eur J Cancer Care (Engl). 2015 May;24(3):436-43. doi: 10.1111/ecc.12260. Epub 2014 Nov 18.
This study evaluated the efficacy of olanzapine in preventing chemotherapy-induced nausea and vomiting (CINV) and improving the quality of life (QoL) of patients with cancer during chemotherapy. Two hundred twenty-nine patients with cancer who received chemotherapy from January 2008 to August 2008 were enrolled, and they were randomised to receive olanzapine or a 5-HT3 receptor antagonist. The patients completed a CINV questionnaire once daily on days 1-5 and a QoL questionnaire on days 0 and 6. The complete response (CR) rates for nausea (76.85% versus 46.2%) and vomiting (84.3% versus 67.6%) were significantly higher in the olanzapine group than in the 5-HT3 receptor antagonist group for delayed CINV but not for acute CINV. The CR rates for nausea (76.85% versus 44.44%) and vomiting (85.95% versus 67.59%) were also significantly higher in the olanzapine group for the 5 days post-chemotherapy. After chemotherapy, global health status, emotional functioning, and insomnia were improved in the olanzapine group but worsened in the 5-HT3 receptor antagonist group, whereas cognitive functioning and appetite loss were unchanged. Moreover, olanzapine significantly improved global health status, emotional functioning, social functioning, fatigue, nausea/vomiting, insomnia, and appetite loss. Olanzapine improved the QoL of patients with cancer during chemotherapy, in part by reducing the incidence of delayed CINV.
本研究评估了奥氮平在预防化疗引起的恶心和呕吐（CINV）以及改善癌症患者化疗期间生活质量（QoL）方面的疗效。纳入了2008年1月至2008年8月接受化疗的229例癌症患者，并将他们随机分为接受奥氮平或5-羟色胺3（5-HT3）受体拮抗剂治疗。患者在第1 - 5天每天完成一次CINV问卷，并在第0天和第6天完成一次QoL问卷。对于延迟性CINV，奥氮平组恶心的完全缓解（CR）率（76.85%对46.2%）和呕吐的CR率（84.3%对67.6%）显著高于5-HT3受体拮抗剂组，但对于急性CINV并非如此。化疗后5天，奥氮平组恶心的CR率（76.85%对44.44%）和呕吐的CR率（85.95%对67.59%）也显著更高。化疗后，奥氮平组的总体健康状况、情绪功能和失眠情况得到改善，而5-HT3受体拮抗剂组则恶化，而认知功能和食欲减退情况未变。此外，奥氮平显著改善了总体健康状况、情绪功能、社会功能、疲劳、恶心/呕吐、失眠和食欲减退。奥氮平改善了癌症患者化疗期间的生活质量，部分原因是降低了延迟性CINV的发生率。
